Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab [5]

Flieger, D., Hainke, S., & Fischbach, W. (2006, September). Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab [5]. Annals of Hematology. https://doi.org/10.1007/s00277-006-0147-8